Sanofi and GlaxoSmithKline’s potential COVID-19 vaccine triggered strong immune responses in all adult age groups in preliminary trials, boosting optimism the shot may join the fight against the pandemic this year.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment